Summary: Persistent challenges in AAV production, including low yields, scalability limitations, and analytical complexity, drive up manufacturing costs and introduce unnecessary risks. Solving these challenges is key to improving both patient outcomes and treatment accessibility, but addressing the root causes requires expertise that bridges molecular design, upstream and downstream process control, and regulatory strategy. Genezen’s integrated plasmid-to-vector platform advances all three, optimizing yield, purity, and reproducibility so developers can scale with confidence from discovery through GMP manufacturing.
What Makes AAV Production So Challenging?
Adeno-associated virus (AAV) vectors are a leading choice for in vivo gene delivery because of their positive safety profile and serotype diversity, which allows for both broad tissue tropism and serotype-dependent specificity. Yet translating research-scale results into reproducible GMP manufacturing presents multiple obstacles.
Vector yield, full-to-empty capsid ratios, and product comparability depend on plasmid quality, production cells, potential transgene toxicity during production, and purification efficiency. These interdependencies make AAV manufacturing uniquely complex. For developers scaling from preclinical to GMP production, these complexities can stall progress. Genezen’s integrated plasmid-to-vector framework bridges those gaps through combined process development, analytics, and regulatory expertise, accelerating readiness for the clinical and commercial stages.
How Can Upstream Optimization Improve AAV Yield?
Every AAV process begins with well thought out plasmid design. Molecular features such as promoter and enhancer selection, gene configuration, and plasmid backbone size all influence transcriptional efficiency and, ultimately, vector yield. Regulatory expectations also extend to design choices: for instance, eliminating antibiotic resistance markers where possible can help avoid additional scrutiny (FDA, 2020).
Transient transfection remains the most flexible approach for clinical-stage programs. Genezen applies high-throughput screening to optimize media, reagents, and DNA-to-cell ratios, using suspension HEK293 systems that scale predictably from 500 mL to over 500 liters. For commercial programs such as Hemgenix®, Genezen also leverages the baculovirus expression platform, which provides robust scalability and consistent yields at large volumes. Across both systems, multivariate design of experiments (DoE) methods link process parameters to increasing full-capsid yield and scalability, driving continuous process improvement.
Key Takeaways:
- High-quality plasmid DNA underpins successful AAV process development.
- DoE accelerates optimization and scalability.
- Integrated plasmid and vector QC ensures reproducibility across batches.
How Is Downstream Purification Evolving to Improve Capsid Quality?
Purification remains a primary bottleneck in AAV production. While traditional cesium chloride (CsCl) gradients have often been viewed as difficult to scale, Genezen continues to leverage CsCl ultracentrifugation extensively as a reliable, platform-agnostic approach to achieve high-purity vector preparations. This method enables precise separation of full and empty capsids, producing a higher-quality product without the extended timelines and costs associated with developing bespoke anion-exchange (AEX) workflows.
In parallel, Genezen also leverages state-of-the-art multi-column chromatography strategies that combine affinity and ion-exchange steps to improve recovery and consistency across different scales. While these processes are generally considered manufacturable and scalable, they do require custom approaches for each transgene to achieve the target product profile necessary. Recent studies have shown that chromatography-based purification can boost recovery and full-capsid enrichment under optimized conditions, achieving up to a threefold increase in full-capsid content and maintaining 70% total capsid recovery during scale-up (Nascimento et al., 2025; Joshi et al., 2021).
AEX remains a common polishing step, enhancing full capsids and reducing the number of empty particles, while new unit operations such as ultrafiltration-based fractionation and monolithic chromatography are emerging as scalable options. Orthogonal analytical tools, including analytical ultracentrifugation (AUC), mass photometry, and charge-detection mass spectrometry (CD-MS), provide quantitative insight into full-to-empty capsid ratios and verify overall vector integrity (Wagner et al., 2023; Lock et al., 2023).
Continuous data feedback between analytical readouts (such as in-line AAVX HPLC or mass photometry) and chromatography development enables real-time process optimization. These feedback loops enhance purification efficiency, process control, and batch-to-batch reproducibility (Vázquez et al., 2023).
Key Takeaways:
- Chromatography-based platforms provide bespoke options for full-capsid enrichment and consistency (Nascimento et al., 2025).
- Ultracentrifuge-based platforms provide agnostic options for full-capsid enrichment and better platformability across multiple transgenes and serotypes.
- Orthogonal analytics quantify full-to-empty ratios and confirm vector integrity (Wagner et al., 2023).
- Continuous data feedback enhances purification efficiency and control (Vázquez et al., 2023).
Why Do Regulatory Expectations Drive Analytical Innovation?
For cell and gene therapy (CGT) products, regulators increasingly focus on analytical consistency and comparability rather than strict adherence to a single platform. Since many of these programs are first-in-class or serve small patient populations, analytical frameworks must clearly understand vector composition, product quality attributes, and clinical relevance across limited data sets.
Recent FDA and EMA guidance recommend that developers establish phase-appropriate, mechanism-based analytical strategies that adapt as a therapy progresses in the clinic. These strategies should show that a product’s identity, purity, and potency are consistently controlled, even when manufacturing scales or processes change (FDA, 2023; FDA, 2020; EMA, 2023).
Genezen’s analytical development approach emphasizes thorough vector characterization, connecting capsid content, genome integrity, and impurity profiling through diverse analytical methods and solid data integration. By aligning analytical results with evolving regulatory expectations, Genezen ensures comparability and quality assurance throughout the product lifecycle, facilitating a smoother transition from preclinical development to GMP clinical and commercial manufacturing.
Genezen’s analytical platform is built to adapt to evolving global regulatory guidance, maintaining scientific rigor and ongoing compliance at every development stage.
Key Takeaways:
- Regulatory agencies emphasize analytical comparability and data consistency across rare and ultra-rare CGT programs (FDA, 2023).
- Mechanism-informed analytical frameworks support product quality without redundant validation (FDA, 2020).
- Integrated data traceability strengthens lifecycle management and regulatory readiness (EMA, 2023).
What’s Next for AAV Manufacturing Innovation?
AAV manufacturing continues to evolve beyond traditional “scale-up by brute force” toward smarter, data-informed production. Across the industry, several innovation paths are shaping the next phase of efficiency and reproducibility.
- Smarter downstream: continuous and high-resolution purification
Advances in multicolumn chromatography (MCC) and related continuous systems are enabling higher productivity and more consistent recovery compared with conventional batch capture. Similarly, twin-column solvent-gradient purification (MCSGP) is showing promise for enhanced polishing resolution and improved full-capsid recovery with reduced buffer use (Neto et al., 2025; Müller et al., 2025). - Progress in producer cell line development
Efforts to develop scalable AAV packaging and producer cell lines remain a focus across the field. Given the cytostatic nature of Rep proteins in the preferred host (HEK293-based) systems, Rep Inducible serum-free suspension HEK293 cell lines have demonstrated potential to mitigate cytotoxicity and support stable AAV packaging line development (Jalšić et al., 2023). The development of producer cell lines would enable continuous inducible production of AVV increasing yield over the traditional transient transfection while lowering costs. - Automation and PAT integration
The adoption of process analytical technologies (PAT), including at-line and in-line chromatographic tools, is improving visibility into critical quality attributes during purification and formulation. These approaches are laying the groundwork for more automated, reproducible, and data-driven manufacturing processes.
Across the industry, facilities equipped with flexible single-use systems, digital data capture, and compatibility with continuous unit operations are best positioned to shorten optimization cycles, reduce variability, and ease tech transfers from development to GMP. Genezen continues to monitor these advances closely, ensuring its platforms remain adaptable as new technologies and regulatory expectations evolve.
Partnering with Genezen: Science Meets Manufacturability
AAV production success depends on controlling complexity without limiting innovation. By integrating plasmid design, scalable bioprocessing, and advanced analytics, Genezen provides the scientific partnership and technical foundation needed to accelerate gene therapy development from concept to commercialization.
Explore our related expertise:
Ready to address your AAV production challenges? Contact our team to discuss how Genezen can strengthen your process development strategy.
Works Cited
“Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs).” U.S. Food and Drug Administration, Jan. 2020, https://www.fda.gov/media/113760/download.
“Guideline on the Quality, Non-clinical and Clinical Aspects of Gene Therapy Medicinal Products (EMA/CAT/80183/2014 Rev.2).” European Medicines Agency, Nov. 2023, https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-non-clinical-clinical-aspects-gene-therapy-medicinal-products_en.pdf.
“Manufacturing Changes and Comparability for Human Cellular and Gene Therapy Products.” U.S. Food and Drug Administration, Aug. 2023, https://www.fda.gov/media/170198/download.
Jalšić, Lovro, et al. “Inducible HEK293 AAV packaging cell lines expressing Rep proteins.” Molecular Therapy: Methods & Clinical Development, vol. 30, 2023, pp. 259–275, doi:10.1016/j.omtm.2023.07.002.
Joshi, P. R. H., et al. “Development of a scalable and robust AEX method for enriched rAAV preparations in genome-containing vectors of serotypes 5, 6, 8, and 9.” Molecular Therapy – Methods & Clinical Development, 2021.
Lock, M., et al. “Orthogonal analytical tools for accurate quantification of full and empty adeno-associated virus capsids.” Molecular Therapy – Methods & Clinical Development, 2023.
Müller, Julia M., et al. “Enrichment of full AAV2 using multicolumn countercurrent solvent gradient purification (MCSGP).” Biotechnology and Bioengineering, vol. 122, no. 9, 2025, pp. 2420–2432, doi:10.1002/bit.29036.
Nascimento, B., et al. “Purification of AAV8 through a scalable two-step monolithic chromatography approach.” Journal of Biotechnology, 2025.
Neto, Salomé, et al. “Improving AAV8 purification with continuous affinity capture: from batch to continuous multicolumn chromatography.” Journal of Biotechnology, vol. 408, 2025, pp. 101–111, doi:10.1016/j.jbiotec.2025.09.003.
Pathak, A., et al. “Data-driven optimization of AAV purification using real-time process analytical technology and feedback control.” Biotechnology Progress, 2025.
Vázquez, E., et al. “Process analytical technology for viral-vector manufacturing: real-time monitoring and control.” Biotechnology Advances, vol. 61, 2023, p. 108065.
Wagner, C., et al. “Quantification of empty, partially filled, and full adeno-associated virus vectors using mass photometry.” International Journal of Molecular Sciences, vol. 24, no. 13, 2023, p. 11033, doi:10.3390/ijms241311033.
Frequently Asked Questions:
- What are the biggest challenges in AAV production?
Maintaining high yield, achieving optimal full-to-empty ratios, and ensuring consistent scalability across production runs.
- How can CDMOs help improve AAV purity?
Through process development expertise, chromatography optimization, and orthogonal analytical validation.
- Why are analytical methods so critical for AAV?
They verify vector potency, integrity, and safety, which are not just critical but indispensable for regulatory approval. This understanding is crucial for all stakeholders in the AAV production process.
- What trends will shape the future of AAV manufacturing?
Automation, continuous purification, and data-driven modeling will enhance efficiency and lower the cost of goods.
